IBJNews

Lilly still waiting on once-weekly Byetta

Back to TopCommentsE-mailPrintBookmark and Share

Is Eli Lilly and Co. about to have another Effient experience?

Lilly and its development partner are trying to get approval for a once-weekly version of the anti-diabetes drug Byetta. The new drug will be called Bydureon.

But the U.S. Food and Drug Administration last week pushed its self-declared deadline for rendering a decision on the drug to Oct. 22. The previous deadline was in March.

Bydureon is key for keeping Lilly competitive in the diabetes game. Earlier this year, the FDA approved a Byetta competitor called Victoza, which is manufactured by Lilly’s diabetes nemesis, Denmark-based Novo Nordisk N/S.

Victoza is a once-daily injectible medicine, compared with the twice-daily injections required with Byetta.

Analysts expect Byetta sales to peak this year at more than $800 million (although Lilly shares that revenue with San Diego-based Amylin Pharmaceuticals Inc.) and then start falling off. But they expect Bydureon sales to reach $800 million to $1 billion by 2015.

Lilly needs to ramp up any new drug as soon as possible so it can build up revenue before Lilly’s bestselling anti-psychotic Zyprexa faces generic competition in October 2011.

Lilly had hoped that the blood thinner Effient would help offset the loss of Zyprexa sales. But the FDA took a year longer than promised to render a decision on the drug. And, because of a severe warning about bleeding causes by the drug, sales so far have been paltry.

ADVERTISEMENT

  • Lilly diabetes treatments
    Conflict of interest.

    Eli Lilly promotes sales of their #1 drug (Zyprexa $4.8 billion year) that can *cause* diabetes and then turn around and make billions selling more drugs to treat the diabetes.

    Eli Lillyâ??s # 1 cash cow Zyprexa has been overprescribed and linked to a ten times greater risk of causing type #2 diabetes and increased risk of heart attacks.

    Daniel Haszard Zyprexa patient who got the diabetes from it

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT